Global Clinical Lead, Hematology — Phase 3 Strategy

Kaye/Bassman International; Cambridge (MA); Presencial; USD 350 000 - 750 000; Tempo integral

Resumo da oferta

Kaye/Bassman International, partnering with a leading global biopharma, seeks an Executive Medical Director to serve as Global Clinical Lead for a late-stage hematology asset.

You will own the clinical strategy for Phase 3, lead a global development team across the US, EU, and Asia, and drive regulatory interactions with FDA and health authorities.

This role offers a path toward VP and potential expansion into additional indications, reporting to the head of clinical development.

Qualificações

• MD or MD/PhD with US clinical training preferred.
• 10+ years in pharma research including 7+ years in Phase I–IV clinical development.
• Phase 3 leadership in hematology or oncology, ideally hematologic malignancies.
• Exposure to NDA/MAA submissions and regulatory interactions.
• Experience leading global, matrixed teams.
• Prior large pharma experience; startup backgrounds not a fit.
• Strong executive presence to influence senior clinical and commercial leaders.

Responsabilidades

• Own clinical strategy for a Phase 3 program in myeloid malignancies, from pivotal execution through registration and toward launch.
• Lead the global development team across the US, EU, and Asia.
• Drive key go/no-go and labeling-critical decisions.
• Lead clinical science interactions with FDA and health authorities.
• Partner with Medical Affairs and senior commercial leadership.
• Report to the head of clinical development with scope to expand into additional indications or earlier-stage programs, and a path toward VP.

Conhecimentos

Executive leadership

Global collaboration

Regulatory interactions

Strategic planning

Formação académica

MD or MD/PhD

US clinical training

Descrição da oferta de emprego

Kaye/Bassman International, partnering with a leading global biopharma, seeks an Executive Medical Director to serve as Global Clinical Lead for a late-stage hematology asset.

You will own the clinical strategy for Phase 3, lead a global development team across the US, EU, and Asia, and drive regulatory interactions with FDA and health authorities.

This role offers a path toward VP and potential expansion into additional indications, reporting to the head of clinical development.